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ABSTRACT 
Since the introduction of antiretroviral therapy (ART), the life expectancy and health quality for patients infected with 
human immunodeficiency virus (HIV) have significantly improved, turning the condition into a chronic disease. As a 
result, this population is now facing not only the deleterious effects of the virus itself and prolonged ART regimens, but 
also the effects of aging. In this regard, cardiovascular diseases have emerged as one of the most common causes of death 
among these patients, who also present a higher rate of outcomes related to coronary heart disease (CHD) when compared 
to the general population. The pathogenesis behind the cardiovascular, HIV-associated complications has been 
demonstrated to be complex and multifactorial, involving traditional cardiovascular disease (CVD) risk factors such as 
lifestyle, metabolic disorders and genetic predisposition, as well as non-traditional risk factors associated with the virus 
itself – immune activation and chronic inflammation – and the metabolic disorders related to ART regimen drugs. 
Therefore, determining the cardiovascular risk of human immunodeficiency virus-infected patients (HIV-IP) as accurately 
as possible, as well as targeting and treating conditions that predispose to CVD, are now emerging concerns among 
physicians. The purpose of this review is to globally explore the new insights on the spectrum of CVD in HIV infection, 
with particular emphasis on CHD and acute coronary syndrome (ACS), as well as the interplay of ART in this setting. 
 
Keywords: cardiovascular disease (CVD), human immunodeficiency virus (HIV), antiretroviral therapy (ART), acute 
coronary syndrome (ACS), coronary heart disease (CHD), atherosclerosis, cardiovascular risk. 
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1. INTRODUCTION  
In 2015, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS), an estimated 36.7 million people 
were living with human immunodeficiency virus (HIV) worldwide, accounting for 1.1 million acquired 
immunodeficiency syndrome (AIDS)-related illnesses by the same year [1]. Despite the documented beneficial effects of 
the introduction in the mid-1990s of highly active antiretroviral therapy (HAART) in the treatment of infected patients 
[2–7], HIV infection remains a leading cause of morbidity and mortality worldwide [5]. Nevertheless, it must be 
highlighted that antiretroviral therapy (ART) has significantly changed the HIV-related illnesses spectrum and the course 
of the disease, since it has evolved from a once fatal infection [8], accounting for high death rates due to AIDS [3,9], into 
a chronic disease [4,10–13]. Nowadays, human immunodeficiency virus-infected patients (HIV-IP) are living longer 
[2,14–18] and with more quality of life from a physical health point of view [3,5,19]. Though, as this population becomes 
older – 50% of HIV-infected individuals who live in Europe and in the United States of America are aged 50 years or 
more [2] – the risk of non-AIDS morbidity and mortality is raising [6,8,20–23]. When compared to the general population, 
non-AIDS related complications tend to appear around a younger age (approximately 10 years before) in infected 
individuals, which suggests an acceleration of the ageing process in the course of the infection [18,24]. Diseases that are 
increasingly more prevalent in the HIV-infected individuals include non-AIDS malignancies, liver and chronic kidney 
disease [9,11,15,17,21,24] as well as clinical and subclinical cardiovascular disease (CVD) [2–4,25–28]. In 2010, 19% of 
HIV-IP had been diagnosed with at least one CVD [29]. The increased risk of the cardiovascular complications previously 
mentioned appear to reflect the interplay of well-known cardiovascular risk factors that are overrepresented in the HIV-
infected population [2,11], such as smoking [11,30,31], the effects of the virus itself [7,15] and the adverse metabolic 
complications of antiretroviral drugs (namely dyslipidemia, insulin resistance, diabetes and lipodystrophy) [3,30–33]. 
Given the fact that HIV infection is an independent risk factor for cardiovascular illnesses [18], there is a need for early 
recognition of HIV-associated complications in the infected population, and particularly, of CVD [34]. Thus, the purpose 
of this review is to explore the new insights on the spectrum of cardiovascular complications in HIV-IP, with particular 
emphasis on coronary heart disease (CHD) and acute coronary syndrome (ACS), as well as the contribution of ART in 
this setting. 
 
2. METHODS 
A literature search using the databases of PubMed, ScienceDirect and Web of Science was performed. Articles up to Mar, 
2017, with no lower date limitation, written in English, Spanish, Portuguese and French were selected for inclusion. The 
most recent articles were chosen whenever possible. The search was conducted using MeSH terms, with the following 
key terms: [human immunodeficiency virus AND (cardiovascular disease OR coronary heart disease) AND (antiretroviral 
therapy AND (cardiovascular disease OR coronary heart disease)]. 
 
3. CARDIOVASCULAR DISEASE IN HIV-INFECTED PATIENTS 
In the years after the detection of the first cases of HIV back in the 1980s, the most frequent cardiovascular complications 
associated with the infection in developed countries were pericarditis, myocarditis caused by opportunistic infections 
[10], dilated cardiomyopathy, pericardial effusion, pulmonary hypertension and cardiac tumours [33]. However, with the 
increasing availability of ART and longer periods of exposure to the therapeutic regimen, opportunistic infections were 
controlled [4] and management of viral load was improved [15], hence changing the spectrum of cardiovascular 
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complications in HIV-IP [35]. Consequently, this population is now presenting a substantially higher incidence and 
mortality rate due to arrhythmias, premature coronary artery disease (CAD) and ACS, particularly myocardial infarction 
(MI) [10,32] (Table 1).  
Still, cardiovascular involvement in treatment-naïve patients is important [15], which leads to the hypothesis that ART 
may not fully explain the increased risk of CVD seen in HIV-IP, and that the virus itself may play its role [36].  
 
Table 1.  Summary data regarding the impact of human immunodeficiency virus (HIV) on cardiovascular disease, particularly 
CAD and ACS.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACS: Acute coronary syndrome; CAD: Coronary artery disease; CI: Confidence interval; CVD: Cardiovascular disease; HIV: Human 
immunodeficiency virus; HR: Hazard ratio; MI: Myocardial infarction; PR: Prevalence ratio. 
Adapted from Shahbaz et al. (2015)[39]. 
 
3.1 Major cardiovascular manifestations  
As previously mentioned, the spectrum of CVD in HIV-infected individuals is broad and may affect the myocardium, 
pericardium, cardiac valves and/or pulmonary vascular beds [41]. The most frequent cardiovascular complications in this 
population include cardiomyopathy, pulmonary arterial hypertension, pericardial disease, cardiac tumours, arrhythmias, 
endocarditis, premature CAD and ACS, including MI [18,36,42].  
Clinically symptomatic cardiomyopathy develops in 1%-2% of patients infected with HIV and usually occurs in the 
context of advanced AIDS stage [22,41]. It is defined as a systolic dysfunction related to a dilation of the left ventricle 
[41], occurring as a result of the direct invasion of myocytes by the HIV [42]. This leads to a lymphocytic infiltrate of the 
myocardium with necrosis of adjacent cells [43]. Among HIV-IP, acute myocarditis is an important cause of 
cardiomyopathy [42] and the possible dysfunction of the left ventricle might determine the progressive development of 
congestive heart failure [15], dilated cardiomyopathy and arrhythmia [43]. Factors that may explain the development of 
cardiomyopathy in the context of HIV infection are the cardiotoxicity of the virus itself [44] and some ART regimen 
drugs [34], nutritional deficiencies (namely vitamin B12, selenium, vitamin B1, carnitine, zinc, and β-carotene) [28] and 
the toxic effects of alcohol and/or illicit drugs [22]. To note, previous studies report a higher proportion of HIV-IP using 
illicit drugs when compared to HIV-uninfected patients [45,46], as well as a higher prevalence of alcohol consumption 
[6].  
Follow-up Size Findings Reference 
 5.9 years 
 
 
82459 
273350 HIV+ 
55109 HIV- 
Increased risk of MI among HIV+ patients 
(HR: 1.48; 95% CI: 1.27-1.72). 
Freiberg et al.[20] 
 5.9 years 81322 
33% HIV+ 
HIV+ veterans without major CVD risk factors had a 2-fold increased risk of 
MI compared with HIV- veterans without major CVD risk factors 
(HR: 2.0; 95% CI: 1.0-3.9). 
Paisible et al.[37] 
 
 6 years 74958 HIV+ The risk of MI was higher in both HIV+ men and women compared with the 
general population; 
Standardized mortality ratio: 1.4 (95% CI: 1.3-1.6) for HIV+ men and 2.7 
(95% CI: 1.8-3.9) for HIV+ women compared with the general population. 
Lang et al.[38] 
 
(data not  
presented in the 
original article[39]) 
618HIV+ 
383HIV- men 
HIV-infected men had a greater prevalence of coronary artery calcification 
(PR: 1.21; 95% CI: 1.08; P=0.001) and any plaque (PR: 1.14; CI: 1.05-1.24; 
P = 0.001), than uninfected men. 
Post et al.[40] 
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Pulmonary hypertension affects an estimated 0.5% of individuals infected with HIV [41]. Though it is a rare condition, 
the mortality rate is high [28] and the 1-year survival rate is reported to range between 51% to 88% [42]. Its 
pathophysiology is thought to be related to the release of endothelin-1 and cytokines such as interleukin-6 (IL-6) and 
tumor necrosis factor (TNF) by HIV-stimulated host-cells, which ultimately causes endothelial damage and consequently 
smooth muscle and fibroblast proliferation [22,42].  
Pericardial disease is also a frequent condition in HIV-IP. Pericardial effusions, unlikely cardiomyopathy, may occur at 
any point in the course of HIV infection [22], being caused by Mycobacterium tuberculosis, fungi, viral and other 
opportunistic microorganisms [41]. In patients with AIDS, it may also be due to metastatic invasion of non-Hodgkin’s 
lymphoma and/or Kaposi’s sarcoma which are the most common cardiac tumours in HIV-infected individuals [22]. As 
in the general population, individuals living with HIV infection are at higher risk of developing metastatic and secondary, 
rather than primary cardiac tumours [28].  
In the context of arrhythmias, several medications used in the treatment of HIV infection are related to QT interval 
prolongation [42] and torsades des pointes [28] which can lead to sudden cardiac death [47]. Hence, it is advisable, as in 
the general population, to perform an electrocardiogram in HIV-IP [35] to assess the presence of ST segment variations 
and the corrected QT (QTc) interval [10,15] before starting HAART [35]. The monitorization of this parameters is 
particularly important when ART is combined with other drugs with a potential QTc interval prolongation effect [15] 
(Table 2). 
 
Table 2.  Drugs commonly used by HIV-infected patients with potential QTc interval prolongation effect.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HAART: Highly active antiretroviral therapy; HIV: 
Human immunodeficiency virus; NNRTIs: Non-
nucleoside reverse transcriptase inhibitors; PIs: 
Protease inhibitors; QTc: Corrected QT. 
Adapted from Fisher et al. (2011)[28], Conte et al. 
(2013)[22] and Pham & Torres (2015)[10]. 
Medication Use in HIV 
NNRTIs  
(In interaction with other classes of drugs, 
e.g. calcium channel antagonists, warfarin, 
β-adrenoceptor antagonists, nifedipine, 
quinidine, corticosteroids and theophylline) 
HAART 
 
 
PIs 
       Ritonavir (may significantly increase            
       the QTc interval when taken with  
       saquinavir) 
Antibiotics 
       Erythromycin 
       Trimethropim/sulfamethoxazole 
       Ciprofloxacin 
       Clarithromycin 
       Pentamidine 
       Pyrimethamine 
       Fluroquinolones  
       Amphotericin B        
      Azole antifungals  
HIV-related infections and opportunistic infections 
Psychotropic agents 
       Tricyclic antidepressants 
       Phenothiazines 
       Haloperidol 
Psychotic disorders 
Antihistamines 
       Astemizole 
       Terfenadine 
Allergic reactions 
Methadone Maintenance treatment of opioid dependency  
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Finally, among the HIV-infected population, infective endocarditis (mainly caused by Staphylococcus aureus and 
Streptococcus viridans) [18] is a manifestation seen almost exclusively in those individuals who concomitantly use drug 
injections [48].  
 
3.2 Pathophysiology of CVD in HIV infection 
The mechanisms proposed to explain the pathogenesis of serious non-AIDS events and the increased cardiovascular risk 
in HIV-IP are multiple and include, among other causes, viral direct effects (persistent immune activation [2], systemic 
inflammation [49,50], endothelial damage and increased thrombotic activity), as well as indirect metabolic disorders 
elicited by the infection itself and as a result of the side effects of prolonged ART therapy [2,17,25,26] (Fig. 1). 
 
 
 
 
Fig. (1). Pathophysiology of CVD in HIV-infected 
patients. 
HIV and antiretroviral treatment (ART) might affect cardiovascular 
disease (CVD) through various pathophysiological pathways 
(together with environmental and genetic factors). HIV and ART 
have direct effects on adipose tissue and liver function with 
subsequent dyslipidemia, lipodystrophy and insulin resistance. 
Other direct impact includes effects on endothelial cells and 
vascular smooth muscle cells leading to vascular and endothelial 
dysfunction with subsequent hypertension, atherosclerosis and 
myocardial infarction. Continuous immune activation and viral 
replication might lead to a permanent T-cell activation which might 
also be affected by a reactivation of other viruses, e.g. 
Citomegalovirus (CMV). ART and HIV might also stimulate a 
chronic status of inflammation and have a complex interaction with 
coagulation factors.  
ART: Antiretroviral therapy; hs-CRP: High-sensitivity C-reactive protein; F VII: Factor VII; FFA: Free fatty acids; HDLc: High-density lipoprotein 
cholesterol; IL6: Interleukin 6; LPS: Lipopolysaccharide; NO: Nitrogen oxide; PAI-1: Plasminogen activator inhibitor type 1; PPARy: Peroxisome 
proliferator-activated receptor; RAS: Renin angiotensin system; ROS: Reactive oxygen species; sCD14: Soluble CD14; sCD163: Soluble CD163.  
Adapted from Hemkens & Bucher (2014)[11]. 
 
3.2.1 The role of traditional risk factors 
As has been documented by previous studies, traditional CVD risk factors that contribute to the pathogenesis of 
cardiovascular conditions appear to be more common in the HIV-infected population [2,11,21]. Triant [51] observed a 
greater incidence of hypertension (HIV: 21.2 vs. non-HIV: 15.9%; p < 0.001), diabetes (HIV: 11.5 vs. non-HIV: 6.6 %; 
p < 0.0001) and dyslipidemia (HIV: 23.3 vs. non-HIV: 17.6 %; p < 0.0001) in HIV-positive patients compared to a control 
group of HIV-negative individuals. 
Dyslipidemia in the HIV infection setting is usually characterized by low high-density lipoprotein (HDL)-cholesterol [52] 
and increased triglyceride concentration [18,53,54]. On the other hand, HIV is an independent risk factor for diabetes 
[52], a well-known component of the metabolic syndrome [55].  
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Others determinants of CVD that appear to be overrepresented in HIV-IP are lifestyle factors (cigarette smoking, 
sedentary life, stress) and abdominal obesity [21]. 
 
3.2.2 The role of the virus: a guilty on its own 
Besides the onset of immunodeficiency, HIV seroconversion is characterized by hyperactivation of both adaptive and 
innate immune systems [23,36,56] and chronic inflammation [23,56]. The continuous immune activation might lead to a 
permanent T-cell, monocyte and macrophage-related state of inflammation [57] that is not completely reversed under 
maintained virological suppression with combined ART [2,17,23,49,51,58–61]. Hence, the persistent virion production 
at low levels enables the inflammatory state to carry on indefinitely [23]. This permanent state of immune activation and 
inflammation observed in HIV-IP may be due to various factors, including: (1) homeostatic drive which might explain 
the impaired immunological and inflammatory response event after the reduction of the initial stimulus [17], (2) 
compromised gut mucosa barrier by rapid depletion of local CD4+ T-cells caused by the virus [6,23], resulting in 
subsequent translocation of microbial products [57,62] like lipopolysaccharides [19,23], that set a persistent state of 
antigen stimulation [52] and might enhance the activation of monocytes and macrophages [11,14,19,23,62–64], (3) 
residual non-detected viremia [19,23] and (4) proinflammatory effects of ART drugs [17].  
The permanent state of inflammation in HIV-infection also causes an interaction with coagulation factors, which usually 
leads to endothelial dysfunction and a hypercoagulation state [2,11,65], increasing the risk for the occurrence of 
cardiovascular events [56].  
On the other hand, HIV is directly implicated in the development of well-known traditional CVD risk factors. In treatment-
naïve patients, the levels of viremia are directly related to elevated serum concentrations of triglycerides and low levels 
of HDL cholesterol [7], which is supported by Gibellini et al. [66], that report alterations in lipoproteins and their 
concentrations determined by the virus, inducing an accelerated development of atherosclerosis. 
Ultimately, increased levels of activated T-cells and monocytes, as well as inflammatory and coagulation markers, are 
ongoing conditions in HIV-IP [6], even with continuous successful ART regimens [56,58,60,67]. However, despite the 
well-documented systemic inflammation in HIV-IP, there has been no proved benefit of adding anti-inflammatory drugs 
to ART on improving clinical CVD endpoints [68]. 
 
3.2.3 The role of antiretroviral therapy 
According to the 2016 recommendations from the European AIDS Clinical Society (EACS), ART must be initiated in all 
HIV-infected persons with primary infection, with the indication to immediate treatment in the following cases: (1) CD4+ 
count less than 350 cells/μL, (2) age ≥ 50 years, (3) concomitant neurological disease, (4) presence of severe or prolonged 
symptoms, and (5) acute infection, which is defined by the detection of p24 antigen and/or human immunodeficiency 
virus-ribonucleic acid (HIV-RNA) in the absence of HIV antibody [69].  
This therapeutic regimen is composed of a minimum of 3 antiretroviral drugs from different classes combined [22,70]. 
The classes that compose ART are protease inhibitors (PIs), nucleoside reverse transcriptase inhibitors (NRTIs), non-
nucleoside reverse transcriptase inhibitors (NNRTIs), integrase inhibitors [36,47] and C-C chemokine receptor 5 (CCR5) 
inhibitors [71,72] (Table 3).  
Currently used ART regimens usually consist of combinations of two NRTIs with either one protease inhibitor, one non-
nucleoside reverse transcriptase inhibitor or one integrase inhibitor (raltegravir) [10,36,70,72] (Table 4).  
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HAART was introduced in the treatment of HIV infection with the goal of restoring CD4+ T-cell immunity by suppressing 
HIV replication [6,22], which on its turn contributes to reduce immune activation and systemic inflammation elicited by 
the virus [17]. Although this goal is broadly achieved in the majority of the patients, the role of HAART in the 
development of CVD in HIV-infected individuals, particularly its contribution to the atherogenic process [4,15,21,46,73], 
is well documented. In a study by Islam et al. [3], a greater risk of CVD in people living with HIV infection was found 
to be associated with ART, particularly with PIs, and prolonged duration of treatment. This study presented a relative risk 
(RR) of 1.52 [95% confidence interval (CI) 1.35-1.70] for CVD in HIV-infected individuals who were treated with ART, 
compared with treatment-naïve HIV-IP, and a RR for CVD of 2.00 (95% CI 1.70–2.37) among HIV-IP on ART compared 
with HIV-uninfected people. Nevertheless, other studies are not in accordance with this findings and document a reduced 
risk of CVD in HIV-IP treated with ART [56,62,74], further highlighting the beneficial effects of this therapeutic regimen 
on suppressing HIV replication [62,74], reducing immune activation [66,74], systemic inflammation [5,62,74] and 
endothelial activation [56].    
 
Table 3.  Classes of antiretroviral therapy (ART) drugs and related adverse cardiovascular effects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CCR5: C-C chemokine receptor 5; DNA: Desoxyribonucleic acid; Glut-4: Glucose transporter type 4; HIV: Human immunodeficiency virus; RNA: 
Ribonucleic acid. 
Adapted from Fisher et al. (2011)[28] and Garg et al. (2013)[36]. 
 
Class Mechanism of action Drugs Cardiovascular effects 
Protease Inhibitors (PIs) 
 
 
 
 
Inhibit the viral protease that 
catalyses the cleavage of viral 
proteins essential for virus 
maturation. 
 
 
 
 
 
Amprenavir 
Atazanavir 
Darunavir 
Fosamprenavir 
Indinavir 
Lopinavir 
Nelfinavir 
Ritonavir 
Saquinavir 
Tipranavir 
Cardiotoxicity due to induction of dyslipidemia 
by mediating the expression of proinflammatory 
cytokines, increasing apoptosis and diminishing 
proliferation of peripheral adipocytes, 
contributing to biosynthesis of triglycerides in 
the liver, and promoting insulin resistance and 
lipodystrophy. 
Nucleoside Reverse 
Transcriptase Inhibitors 
(NRTIs) 
Inhibit reverse transcriptase, the 
enzyme involved in conversion of 
single-stranded HIV RNA into 
double-stranded DNA. 
Abacavir 
Didanosine 
Tenofovir 
Emtricitabine 
Lamivudine 
Stavudine 
Zidovudine 
Cardiotoxicity due to direct effect on 
mitochondrial enzymes, inhibition of nucleoside 
transport, inhibition of nucleoside 
phosphorylation and generation of reactive 
oxygen species in the mitochondria. 
Non-Nucleoside Reverse 
Transcriptase Inhibitors 
(NNRTIs) 
 
Inhibit reverse transcriptase, the 
enzyme involved in conversion of 
single-stranded HIV RNA into 
double-stranded DNA. 
Efavirenz 
Etravirine 
Nevirapine 
Rilpivirine 
 
Pharmacological interaction with other classes of 
drugs, e.g. calcium channel antagonists, 
warfarin, beta-adrenoceptor antagonists, 
nifedipine, quinidine, corticosteroids and 
theophylline. 
Integrase inhibitors 
 
Inhibit the viral integrase enzyme 
that catalyses the insertion of 
proviral DNA into the host 
genome. 
Raltegravir 
 
No specific cardiovascular side effects or drug 
interactions reported so far. 
Entry and fusion inhibitors Inhibit viral entry into host cells. 
Inhibit binding of HIV envelope 
glycoprotein to the CCR5 co-
receptor. 
Maraviroc 
Enfuvirtide 
No specific cardiovascular side effects or drug 
interactions reported so far. 
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Table 4.  Initial combination ART regimens for adult HIV-positive persons (one of the following to be selected). 
Regimen Dosing Cautions 
2 NRTIs + INSTI 
ABC/3TC/DTG(I,II) ABC/3TC/DTG 600/300/50 mg, 1 tablet qd 
 
Al/Ca/Mg-containing antacids or multivitamins should be 
taken well separated in time (minimum 2h after or 6h 
before). 
DTG 50 mg bid with rifampicin. 
 
TAF/FTC(III) 
or 
TDF/FTC(IV,V) + DTG 
TAF/FTC 25/200 mg, 1 tablet qd or 
TDF/FTC 300/200 mg, 1 tablet qd 
+ DTG 50 mg, 1 tablet qd 
 
TAF/FTC(III) 
or 
TDF/FTC(IV,V) + RAL 
TAF/FTC/RPV 25/200/25 mg, 1 tablet qd or TDF/FTC/RPV 
300/200/25 mg, 1 tablet qd 
Co-administration of antacids containing Al or Mg not 
recommended. 
RAL 400 or 800 mg bid with rifampicin. 
 
TAF/FTC/EVG/c(III) 
or 
TDF/FTC/EVG/c(IV,VI) 
 
TAF/FTC/EVG/c 10/200/150/150 mg, 1 tablet qd or 
TDF/FTC/EVG/c 300/200/150/150 mg, 1 tablet qd 
Al/Ca/Mg-containing antacids or multivitamins should be 
taken well separated in time (minimum 2h after or 6h 
before). 
 
2 NRTIs + NNRTI 
TAF/FTC/RPV(III) 
or 
TDF/FTC/RPV(IV) 
TAF/FTC/RPV 25/200/25 mg, 1 tablet qd or TDF/FTC/RPV 
300/200/25 mg, 1 tablet qd 
Only if CD4 count > 200 cells/µL and HIV-VL < 100,000 
copies/mL. 
PPI contra-indicated. 
H2 antagonists to be taken 12h before or 4h after RPV. 
 
2 NRTIs + PI/r or PI/c 
TAF/FTC(III) 
or 
TDF/FTC(IV,V) + DRV/c  
or + DRV/r 
 
TAF/FTC 10/200 mg, 1 tablet qd or  
TDF/FTC 300/200 mg, 1 tablet qd  
DRV/c 800/150 mg, 1 tablet qd or  
+ DRV 800 mg, 1 tablet qd + RTV 100 mg, 1 tablet qd 
 
Monitor in persons with a known sulfonamide allergy. 
 
(I) ABC contra-indicated if HLA-B*5701 positive. ABC should be used with caution in persons with a high CVD risk (>20%). 
(II) Use this combination only if HBsAg-negative. 
(III) In certain countries TDF is labelled as 245mg rather than 300mg to reflect the concentration of the active metabolite (tenofovir disoproxil). When 
available, combinations containing TDF can be replaced by the same combinations containing TAF, especially in elderly HIV-positive persons or in 
HIV-positive persons with or at increased risk of osteoporosis or renal impairment. Use TAF/FTC/EVG/c only if eGFR >30mL/min. TAF is used at 
10mg when co-administered with drugs that inhibit P-gp and at 25mg when co-administered with drugs that do not inhibit P-gp. 
(IV) Avoid TDF if osteoporosis, renal monitoring required. 
(V) If TDF/FTC is not available, one alternative could be TDF+3TC as separate entities. 
(VI) TDF/FTC/EVG/c use only if eGFR ≥70 mL/min. It is recommended that TDF/FTC/EVG/c is not initiated in persons with eGFR < 90 mL/min unless 
this is the preferred treatment. 
3TC: Lamivudine; ABC: Abacavir; ART: Antiretroviral therapy; bid: Twice daily; CVD: Cardiovascular disease; DRV: Darunavir; DTG: Dolutegravir; 
eGFR: Estimated glomerular filtration rate; EVG: Elvitegravir; FTC: Emtricitabine; HIV: Human immunodeficiency virus; HIV-VL: Human 
immunodeficiency virus-viral load; INSTI: Integrase strand transfer inhibitor; NNRTI: Non-nucleoside reverse transcriptase inhibitors; NRTIs: 
Nucleos(t)ide reverse transcriptase inhibitors; P-gp: P-glycoprotein 1; PI: Protease inhibitors; PI/c: Protease inhibitors pharmacologically boosted with 
cobicistat; PI/r: Protease inhibitors pharmacologically boosted with ritonavir; PPI: Proton pump inhibitor; qd: Once daily; RAL: Raltegravir; RPV: 
Rilpivirine; TAF: Tenofovir alafenamide; TDF: Tenofovir disoproxil fumarate. 
Adapted from Battegay et al. (2016)[69]. 
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3.2.3.1 The metabolic effects of antiretroviral therapy 
HIV-infected individuals receiving ART present a cluster of metabolic complications [36] namely dyslipidemia [5,11,73] 
with elevated triglycerides [19,75] and low-density lipoprotein (LDL) cholesterol [11,18], impaired glucose metabolism 
[5,19,25] and lipodystrophy [11,13,21,25,71] (Table 5).  
 
Table 5.  Common adverse metabolic and cardiovascular effects associated to antiretroviral drugs. 
Antiretroviral class Drugs 
Effects 
Cardiovascular Body fat Metabolic 
Protease Inhibitors 
(PIs) 
 
 
Atazanavir(I) 
Darunavir(I) 
Fosamprenavir(II) 
Indinavir(II) 
Lopinavir 
Saquinavir(II) 
Tipranavir(II) 
 
 
Ischaemic heart disease 
Ischaemic heart disease 
Ischaemic heart disease 
 
 
 
↑ Abdominal fat 
Dyslipidemia 
Dyslipidemia 
Dyslipidemia 
Dyslipidemia, Diabetes mellitus 
Dyslipidaemia 
Dyslipidaemia 
Dyslipidaemia 
Nucleoside Reverse 
Transcriptase 
Inhibitors (NRTIs) 
 
Abacavir 
Didanosine(III) 
Tenofovir(IV) 
Emtricitabine 
Lamivudine 
Stavudine(III) 
Zidovudine(III) 
Ischaemic heart disease 
Ischaemic heart disease 
 
 
 
 
 
 
Lipoatrophy 
Lipoatrophy 
 
Hyperlactaemia 
 
 
 
Dyslipidaemia, Hyperlactaemia 
Dyslipidaemia, Hyperlactaemia 
Non-Nucleoside 
Reverse Transcriptase 
Inhibitors (NNRTIs) 
 
Efavirenz 
Etravirine 
Nevirapine 
Rilpivirine 
 
 
 Dyslipidaemia, Gynaecomastia 
CCR5 inhibitor Maraviroc Ischaemic heart disease   
 
(I) ATV can be used unboosted, or boosted with low-dose RTV or COBI. ATV-related adverse effects are more common with boosting. DRV can be 
used boosted with low-dose RTV or COBI. Both low-dose RTV and COBI as boosters may cause similar minor digestive problems. 
(II) Still available but seldom used. Requires RTV-boosting.  
(III) Still available, but generally not recommended due to toxicity. 
(IV) TDF has been the classical prodrug of tenofovir. TAF may have a lower risk of tenofovir-related kidney and bone adverse effects but long-term 
experience is lacking. 
ATV: Atazanavir; CCR5: C-C chemokine receptor 5; COBI: Cobicistat; DRV: Darunavir; RTV: Ritonavir; TAF: Tenofovir alafenamide; TDF: 
Tenofovir disoproxil fumarate. 
Adapted from Battegay et al. (2016)[69]. 
 
Individuals treated with older antiretroviral drugs like PIs [71], may develop lipoatrophy in the face and limbs as well as 
lipohypertrophy with central visceral fat gain [4,11,31,65], fat deposition on the neck region (“buffalo hump”) [4,11] or 
ectopic fat deposition in the myocardium. In particular, ectopic fat deposition in cardiomyocytes might be one possible 
mechanism contributing to the high CVD burden observed in HIV-IP treated with HAART [76]. On the other hand, 
lipodystrophy in this patients is also a risk factor for pancreatic β-cell dysfunction [52] which might exacerbate insulin 
resistance [13] and thus leading to the development of diabetes [14]. 
It has been shown that PIs induce metabolic changes [75,77,78] like dyslipidemia [2,28,79] and insulin resistance [72], 
contributing to the formation of atherosclerotic lesions [22,28,46,65].  
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Among other causes, the lipid metabolism impairment with PIs seems to be associated with the activation of endoplasmic 
reticulum (ER) stress in adipocytes, hence disrupting the expression of key regulatory genes [80] (Fig. 2). PIs also appear 
to be directly related to an increased risk of ACS, particularly, MI [14,54] (Table 6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Mechanisms of PIs-induced dyslipidemia. 
Proposed mechanisms for PIs-based dyslipidemia include the following aspects: (1) There is structural similarity with the amino acid sequence of the 
C-terminal region of cytoplasmic retinoic acid-binding protein type 1 (CRABP1); thus, the PIs likely bind to CRABP-1, increasing apoptosis and 
diminishing the proliferation of peripheral adipocytes; (2) PI-mediated increases in the expression and secretion of proinflammatory cytokines, such as 
tumor necrosis factor alpha, interleukin-1β and interleukin-6 are involved in altered adipocyte functions and decreased adiponectin; (3-4) PI-induced 
dyslipidemia is based on the structural similarity between the catalytic region of HIV-1 protease and the LDL-receptor-related protein that interferes 
with lipoprotein lipase complex formation (LRP-LPL); as a result, the adipose storage capacity is reduced and plasma TG-rich lipoproteins are increased; 
(5) PI suppresses proteasome-mediated degradation of the sterol regulatory element binding proteins (SREBP) in the liver and adipocytes, which are 
transcription factors responsible for fatty acid and triglyceride synthesis in the liver and adipose tissue and control several steps of cholesterol synthesis; 
the suppression promotes nSREBP accumulation in the liver and an increase in the biosynthesis of total cholesterol, triglycerides and adipose tissue, 
promoting increased insulin resistance, reduced expression of leptin and lipodystrophy; (6) PI-based therapy increases the hepatic synthesis of 
triglycerides, and to a lesser extent, very-low density lipoprotein cholesterol.  
PIs: Protease inhibitors; HDL: High-density lipoprotein; TG: Triglycerides; LDL: Low-density lipoprotein; CRABP1: C-terminal region of cytoplasmic 
retinoic acid-binding protein type 1; TNF-α: Tumor necrosis factor alpha; IL-1β: Interleukin 1β; IL-6: Interleukin-6; LRP: LDL-receptor-related protein; 
LPL: Lipoprotein lipase; TG-RLP: Triglyceride-rich lipoproteins are increased; SREBP: Sterol regulatory element binding proteins; VLDL: Very-low 
density lipoprotein; RXR-PPARγ: Retinoid X receptor-peroxisome proliferator-activated receptor γ; LDL-R: Low-density lipoprotein-receptor; PCSK9: 
Proprotein convertase subtilisin-kexin type 9; SCAP: Sterol regulatory element binding protein cleavage activating protein; S1P: Site 1 protease; S2P: 
Site 2 protease.  
Adapted from da Cunha et al. (2015)[81]. 
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Table 6.  Summary of studies regarding the risk of MI among HIV-infected individuals treated with PIs.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HIV: Human immunodeficiency virus; MI: Myocardial infarction; OR: Odds ratio; PIs: Protease inhibitors; RR: Relative risk. 
 
Similarly to PIs, NRTIs older drugs (zidovudine [10], stavudine and didanosine [53]) induce dyslipidemia [53,85] and 
insulin resistance. A relationship between older generation NRTIs and lipoatrophy has also been described [85]. However, 
and according to Kelesidis & Currier [7], other drugs from this class, namely tenofovir, lamivudine and emtricitabine, 
seem to not be associated with lipid metabolism impairment, although other authors disagree with these findings (Table 
7).  
Globally, PIs and NRTIs are associated with a higher risk of CVD events. Tripathi et al. [32] report the RR of CVD 
associated with PIs and NRTIs to be 1.11 (95% CI 1.05–1.17) and 1.05 (95% CI 1.01–1.10) per year of exposure, 
respectively.  
Among integrase inhibitors, raltegravir has shown no deleterious effects on the lipid metabolism [2] nor in the 
cardiovascular system [72,74]. The same metabolic and neutral cardiovascular effect profile has been exhibited by some 
NNRTIs [36,53,86] and newer classes of ART drugs like CCR5 inhibitors [53,74] (Table 7.A).  
Given the toxicity associated with some ART drugs, HIV-infected individuals should be therefore evaluated for serum 
concentration of lipids and fasting blood glucose levels before the initiation of HAART [48], at 3 to 6 months after 
initiation [18,34], and once each year [28] in the absence of abnormalities [70] (Table 8). 
 
Table 7.  Metabolic disorders associated with ART drugs: glucose and lipid metabolism impairment (A) and HIV-associated 
lipodystrophy syndrome (B). 
 
A – Global impact of HAART drugs on glucose and lipid metabolism[81,87]. 
Antiretroviral class Drugs Effects on glucose 
                                                  Effects on lipids 
 TG LDL HDL 
Protease Inhibitors 
(PIs) 
 
Amprenavir/ritonavir 
Atazanavir/ritonavir 
Darunavir/ritonavir 
Fosamprenavir/ritonavir   
Indinavir 
Lopinavir/ritonavir 
Nelfinavir 
Saquinavir  
Tipranavir/ritonavir 
Insulin resistance 
Insulin resistance 
Insulin resistance 
Insulin resistance 
Insulin resistance 
Insulin resistance 
Insulin resistance 
Insulin resistance 
Insulin resistance 
↑↑↑ Dyslipidemia 
a) 
↑ Dyslipidemia 
↑↑↑ Dyslipidemia 
↑↑ Dyslipidemia 
↑↑↑ Dyslipidemia 
↑↑ Dyslipidemia 
↑ Dyslipidemia 
↑↑↑ Dyslipidemia 
Increase 
 
Increase 
Increase 
 
Increase 
 
 
Increase 
Increase 
 
Increase 
Increase 
 
Increase 
 
 
Increase 
Same/decrease 
 
Same/decrease 
Same/decrease 
 
Same/decrease 
 
 
Same/decrease 
 
Study Findings Reference 
Case-control study 
289 cases (patients with     
prospectively recorded first MI) 
884 controls 
Cumulative exposure to any protease inhibitor was associated with an 
increased risk of MI, except for saquinavir 
(OR: 1.15; 95% CI: 1.06-1.26, per year). 
 
Lang et al.[82] 
Multi-cohort study 
[Data Collection on Adverse Events 
of Anti-HIV Drugs (D:A:D) study] 
 
Cumulative exposure to indinavir or lopinavir/ritonavir was associated with 
an increased risk of MI (relative rate [RR] per year, 1.12 and 1.13, 
respectively); 
No association for saquinavir or nelfinavir was found. 
Worm et al.[83] 
Meta-analysis 
27 studies (8 studies included in 
formal meta-analysis) 
Increased risk of MI for patients recently exposed (usually defined as within 
last 6 months) to PIs (RR: 2.13; 95% CI 1.06-4.28). 
 
Bavinger et al.[84] 
Meta-analysis 
11 studies 
Incidence of MI in patients exposed to PIs showed an overall significant 
risk (OR: 2.68; 95% CI 1.89-3.89). 
D’Ascenzo et al.[8] 
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Table 7. Contd 
Antiretroviral class Drugs Effects on glucose 
                            Effects on lipids 
 TG LDL HDL 
Nucleoside Reverse 
Transcriptase 
Inhibitors (NRTIs) 
 
Abacavir 
Didanosine 
Tenofovir 
Emtricitabine 
Lamivudine 
Stavudine 
Zidovudine 
No effect 
Insulin resistance 
No effect 
No effect 
No effect 
Insulin resistance 
Insulin resistance 
↑ Dyslipidemia 
↑↑ Dyslipidemia 
↑ Dyslipidemia 
↑ Dyslipidemia 
↑ Dyslipidemia 
↑↑ Dyslipidemia 
↑↑ Dyslipidemia 
Increase 
 
Increase 
Increase 
 
Increase 
Increase 
Increase 
 
Increase 
Increase 
 
Increase 
Increase 
Increase 
 
Increase 
Increase 
 
Increase 
Increase 
Non-Nucleoside 
Reverse 
Transcriptase 
Inhibitors (NNRTIs) 
Efavirenz 
Etravirine 
Nevirapine 
Rilpivirine 
No effect 
No effect 
 
 
↑ Dyslipidemia 
Neutral effect 
↑Dyslipidemia 
Neutral effect 
Increase 
 
Increase 
Increase 
 
Increase 
Increase 
 
Increase 
Integrase inhibitors 
 
Dolutegravir 
Elvitegravir 
Raltegravir 
No effect 
No effect 
No effect 
Neutral effect 
Neutral effect 
Neutral effect 
 
Increase 
 
Increase 
 
Increase 
Entry and fusion 
inhibitors 
Maraviroc 
Enfuvirtide 
No effect 
No effect 
Neutral effect 
Neutral effect 
   
 
a) Atazanavir is an exception to all ritonavir boosted PIs, since it has fewer effects on the lipid profile. 
ART: Antiretroviral therapy; HAART: Highly active antiretroviral therapy; HDL: High-density lipoprotein; HIV: Human 
immunodeficiency virus; LDL: Low-density lipoprotein; NNRTIs: Non-nucleoside reverse transcriptase inhibitors; NRTIs: 
Nucleoside reverse transcriptase inhibitors; PIs: Protease inhibitors; TG: Triglycerides. 
 
B – Prevention and management of lipodistrophy, according to European AIDS Clinical Society (2016)[69]. 
 
Lipoatrophy Lipohipertrophy 
Clinical findings[81] Sunken eyes and/or cheeks, prominent zygomatic 
arch, prominent veins, skinny or muscular appearance, 
loose skin folds 
Increased abdominal girth with visceral fat accumulation, 
dorsocervical or supraclavicular fat pad 
 
Prevention • Avoid stavudine and zidovudine or pre-emptively 
switch away from them 
• Avoid excessive weight loss due to diet and exercise 
• Avoid inhaled fluticasone (and potentially other inhaled 
corticosteroids) with ritonavir or cobicistat-boosted PIs as it 
may cause Cushing syndrome or adrenal insufficiency 
Management • Modification of ART 
–– Switch stavudine or zidovudine to abacavir or 
tenofovir (only ART modification proven to 
partially restore subcutaneous fat; increase in total 
limb fat ~400-500 g/year) 
–– Switch to regimen not including NRTIs 
(increase in total limb fat ~400-500 g/year) 
• Surgical intervention 
–– For cosmetic relief of (facial) lipoatrophy 
• Diet and exercise may reduce visceral adiposity 
–– Limited data, but possible reduction in visceral 
adipose tissue and improvement in insulin sensitivity 
and blood lipids 
–– May worsen subcutaneous lipoatrophy 
• Pharmacological interventions to treat lipohypertrophy 
have not been proven to provide long-term effects 
• Growth hormone (not approved for this indication in 
Europe) 
–– Decreases visceral adipose tissue 
–– May worsen subcutaneous lipoatrophy and insulin 
resistance 
• Tesamorelin (not approved in Europe) 
• Metformin (not approved for this indication in Europe) 
–– Decreases visceral adipose tissue in insulin resistant 
people 
–– May worsen subcutaneous lipoatrophy 
• Surgical therapy can be considered for localised 
lipomas/”buffalo humps” 
 
AIDS: Acquired immunodeficiency syndrome; ART: Antiretroviral therapy; NRTIs: Nucleoside reverse transcriptase inhibitors; 
PIs: Protease inhibitors. 
 
Adapted from da Cunha et al. (2015)[81], Battegay et al. (2016)[69] and Seecheran et al. (2017)[87].  
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Table 8.  Assessment of cardiovascular risk factors for ART-naïve HIV-infected individuals, according to European AIDS 
Clinical Society (2016).  
 
 
 
 
 
 
 
 
 
ART: Antiretroviral therapy; ECG: Electrocardiogram; HDL-c: 
High-density lipoprotein cholesterol; HIV: Human 
immunodeficiency virus; LDL-c: Low-density lipoprotein 
cholesterol; TC: Total cholesterol; TG: Triglycerides. 
Adapted from Battegay et al. (2016)[69]. 
 
Taken together, in spite of the CVD risk that has been proven to be associated with ART, the beneficial effects of this 
therapeutic regimen (by reducing CVD-related morbidity and mortality in HIV-IP [11,88]) appear to outpass the risks 
[4,14,15,17,30,41,51]. Furthermore, the Strategies for Management of Antiretroviral Therapy (SMART) trial showed that 
ART interruption in patients with chronic HIV infection whose CD4 cell count reached greater than 350 cells/mm3, was 
associated with a higher rate of major cardiovascular events when compared to HIV-IP receiving continuous treatment 
[hazard ratio (HR) 1.6; 95% CI 1.0–2.5] [89].  
Nevertheless, health care providers should be aware of the multiple pharmacological interactions between ART 
components and other class drugs (Table 9), that may aggravate HAART-associated cardiovascular complications, 
abolish or reduce the therapeutic effect of other concomitant treatment regimens and/or lead to the development of adverse 
reactions [69].    
 
Table 9.  Drug-drug interactions between antiretroviral drugs and non-antiretroviral cardiovascular drugs. 
 
ATV/r DRV/c DRV/r LPV/r EFV ETV NVP RPV MVC EVG/c TAF TDF 
A
N
T
IH
Y
P
E
R
T
E
N
S
IV
E
S
 
A
C
E
 i
n
h
ib
it
o
r
s 
cilazapril             
enalapril             
lisinopril             
perindopril             
quinalapril             
ramipril             
trandolapril             
A
n
g
io
te
n
si
n
 a
n
ta
g
o
n
is
ts
 candesartan              
irbesartan ↓  ↓ ↓ ↑ ↑    ↓   
losartan ↓a)  ↓a) ↓a) ↑b) ↑b)    ↓a)   
olmesartan             
telmisartan             
valsartan             
β
 b
lo
ck
er
s 
atenolol ↔c)   ↔c)         
bisoprolol ↑c) ↑ ↑ ↑c) ↓ ↓ ↓   ↑   
carvedilol ↑↓c) ↑ ↑↓ ↑↓c) ↑↓ ↑↓    ↑   
metoprolol ↑c) ↑ ↑ ↑c)      ↑   
propanolol ↑c) ↑ ↑ ↑c)      ↑   
 
At HIV 
diagnosis 
Before 
starting 
ART 
Follow-up 
frequency 
Body composition 
       Body-mass index 
+ + Annual 
Cardiovascular disease risk 
       Framingham score 
+ + 2 years 
ECG 
+ +/- 
As indicated for 
each case 
Hypertension 
       Blood pressure 
+ + Annual 
Lipids 
      TC, HDL-c, LDL-c, TG 
+ + Annual 
Glucose 
      Serum glucose 
+ + Annual 
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Table 9. Contd 
 ATV/r DRV/c DRV/r LPV/r EFV ETV NVP RPV MVC EVG/c TAF TDF 
A
N
T
IH
Y
P
E
R
T
E
N
S
IV
E
S
 
C
a
lc
iu
m
 c
h
a
n
n
e
l 
b
lo
ck
er
s 
amlodipine ↑d) ↑ ↑ ↑e) ↓ ↓ ↓   ↑   
diltiazem ↑ d) ↑ ↑ ↑ e) ↓ ↓ ↓   ↑   
felidipine  ↑ d) ↑ ↑ ↑ e) ↓ ↓ ↓   ↑   
lacidipine  ↑ d) ↑ ↑ ↑ e) ↓ ↓ ↓   ↑   
lercanidipine     ↓ ↓ ↓      
nicardipine ↑ d) ↑ ↑ ↑ e) ↓ ↓ ↓   ↑   
nifedipine ↑ d) ↑ ↑ ↑ e) ↓ ↓ ↓   ↑   
nisoldipine ↑ d) ↑ ↑ ↑ e) ↓ ↓ ↓   ↑   
verapamil ↑ d) ↑ ↑ ↑ e) ↓ ↓ ↓   ↑   
D
iu
r
e
ti
cs
 
amiloride             
chlortalidone             
furosemide             
indapamide ↑ ↑ ↑ ↑ ↓ ↓ ↓   ↑   
torasemide ↓  ↓ ↓ ↑ ↑    ↓   
O
th
e
r
s doxazosin ↑ ↑ ↑ ↑ ↓ ↓ ↓   ↑   
spironolactone             
A
N
T
IC
O
A
G
U
L
A
N
T
S
 
acenocoumarol ↓  ↓ ↓ ↓ ↑ ↓   ↓   
apixaban     ↓ ↓ ↓   ↑   
dabigatran ↑ ↑ ↑ ↑?    ↑?  ↑   
dalteparin             
edoxaban ↑ ↑ ↑ ↑      ↑   
enoxaparin             
fondaparinux             
heparin             
rivaroxaban     ↓ ↓ ↓   ↑   
warfarin ↑or↓f) ↑ ↓ ↓ ↑or↓ ↑ ↑or↓   ↓   
A
N
T
IP
L
A
T
E
L
E
T
 
A
G
E
N
T
S
 
 
aspirin            g) 
clopidogrel ↓h) ↓h) ↓h) ↓h) ↑i) ↓h) ↑i)   ↓h)   
dipyridamole ↓j)  ↓ ↓ ↓ ↓       
prasugrel          k)   
ticagrelor     ↓ ↓ ↓   ↑   
 
↑ potential elevated exposure of the non-ARV drug; ↓ potential decreased exposure of the non-ARV drug; ↔ no significant effect; a) [parent drug] 
decreased but [active metabolite] increased; b) [parent drug] increased but [active metabolite] decreased; c) risk of PR interval prolongation; d) ECG 
monitoring recommended; e) use with caution as both LPV and calcium channel blockers prolong the PR interval; clinical monitoring is recommended; 
f) unboosted ATV predicted to increase the anticoagulant, monitor INR and adjust the anticoagulant dosage accordingly; g) potential risk of 
nephrotoxicity, monitor renal function; h) decreased conversion to active metabolite leading to non-responsiveness to clopidogrel; an alternative to 
clopidogrel should be considered; i) increase in amount of active metabolite via induction of CYP3A4 and CYP2B6; j) unboosted ATV predicted to 
increase dipyridamole exposure due to UGT1A1 inhibition; k) reduced active metabolite, but without a significant reduction in prasugrel activity. 
no clinically significant interaction expected 
these drugs should not be co-administered 
potential interaction, which may require a dosage adjustment or close monitoring 
potential interaction predicted to be of weak intensity (< 2 fold ↑AUC or < 50% ↓AUC). A dosage adjustment is a priori not recommended 
Note: DTG, RAL, ABC, FTC, 3TC and ZDV, which are not represented in the table, present no significant drug-drug interactions with antiplatelet 
agents, anticoagulants nor antihypertensive drugs. 
3TC: Lamivudine; ABC: Abacavir; ARV: Antiretroviral; ATV/r: Atazanavir pharmacologically boosted with ritonavir; AUC: Area under the curve; 
DRV/c: Darunavir pharmacologically boosted with cobicistat; DRV/r: Darunavir pharmacologically boosted with ritonavir; DTG: Dolutegravir; ECG: 
Electrocardiogram; EFV: Efavirenz; ETV: Etravirine; EVG/c: Elvitegravir pharmacologically boosted with cobicistat; FTC: Emtricitabine; LPV: 
Lopinavir; Lopinavir/r: Lopinavir pharmacologically boosted with ritonavir; MVC: Maraviroc; NVP: Nevirapine; RAL: Raltegravir; RPV: Rilpivirine; 
TAF: Tenofovir alafenamide; TDF: Tenofovir disoproxil fumarate; UGT1A1: UDP glucuronosyltransferase family 1 member A1; ZDV: Zidovudine. 
Adapted from Battegay et al. (2016)[69]. 
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3.3 Atherosclerosis and HIV infection: the host, the virus and the therapeutic 
perspective 
The development of atherosclerosis in HIV-IP is a complex and multifactorial process in which the effects of the virus 
per se [14,90], higher exposure to traditional CVD risk factors [14,50] and long-term ART treatment [14,90–92] intervene 
simultaneously (Fig. 3).  
 
 
 
 
 
 
Fig. (3). Factors contributing to 
atherosclerosis in HIV-infected 
individuals. 
Atherosclerosis and arterial disease in 
human immunodeficiency virus (HIV)-
infected individuals is a multifactorial 
process involving the virus, 
antiretroviral therapy, traditional risk 
factors for CVD and genetic 
predisposition. Each arrow represents a 
potential target for research and 
therapeutic intervention. 
Adapted from Stein et al.(2014)[50].    
 
 
 
The stimulation of proatherogenic mechanisms in HIV infection (Fig. 4) is intimately related to the ability of the virus 
and particularly some viral proteins to elicit endothelial activation, increase endothelial permeability and promote 
apoptosis [66]. Thus, endothelial dysfunction is perceived as an impaired ability of the vascular lining to maintain normal 
homeostasis and occurs in the early stages of atherogenesis [49,72]. 
An impaired endothelium facilitates the entrance of plasma lipids like LDL into the subendothelial space, where, due to 
the excessive concentration of free radicals [25], the particles are oxidized [16]. Oxidized low-density lipoproteins then 
penetrate the intima of the arterial wall, triggering the exposure of monocyte chemoattractant protein-1 (MCP-1) [93], 
which promotes the recruitment of circulating leukocytes (namely monocytes) [66]. The so recruited leukocytes up-take 
oxidized low-density lipoproteins forming “foam cells” [22,94] that release inflammatory cytokines such as tumor 
necrosis factor-α (TNF-α), interferon-γ (IFN-γ) [25], interleukin-1 (IL-1), IL-6 and interleukin-8 (IL-8) [28,95], as well 
as vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), E-selectin [56,95] and von 
Willebrand factor (vWF) [28,95]. In the particular setting of HIV infection, the synthesis of inflammatory cytokines by 
macrophages and the expression of adhesion molecules appear to be closely related to the action of HIV trans-activator 
of transcription (Tat) protein [66], leading to endothelial activation and increased endothelial permeability [95]. 
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Besides being the hallmark of the atherogenic process, endothelial dysfunction also contributes to a hypercoagulability 
state [25]. Platelets interact with exposed sub-endothelial structures when the endothelium is injured through adhesive 
receptors on both platelets and endothelial cells, thus initiating the aggregation process. Platelet activation in the presence 
of endothelial dysfunction might also be explained by loss of platelet-inhibiting mediators namely nitric oxide (NO) and 
prostacyclin (PGI2) [95]. On the other hand, viral replication itself may partially promote coagulation by up-regulating 
tissue-factor pathways [73]. 
Although the atherosclerotic process may be similar in both HIV-infected and non-infected populations, the accelerated 
atherogenic process that occurs in the course of the infection [6,25,96,97] is characterized by an increased formation of 
non-calcified [25,50,98,99] atypical plaques [31], that due to their thin fibroatheroma caps are prone to erosion [46] or 
rupture [19,31,99], thus conditioning a higher risk of CVD-related events [31,74,100]. Furthermore, endothelial 
dysfunction is more prevalent in untreated HIV-IP when comparing with age and gender-matched controls [56], and the 
macrophage activation that occurs in HIV infection and actively contributes to subclinical atherosclerosis [11] is 
independent of traditional CVD risk factors [64].  
Another possible explanation for the ongoing development of chronic inflammatory conditions in HIV-infected 
individuals, such as atherosclerosis, is the activity of negative regulatory factor (Nef) protein (Fig. 4). This protein, 
encoded by lentoviruses like HIV-1, is transferred from circulating monocytes and T-cells infected by the virus into 
endothelial cells, conditioning activation of the endothelium. On another hand, this activation process, particularly in the 
pro-inflammatory state that characterizes HIV infection, leads to increased chemokine expression, thus promoting T-cell 
and monocyte adherence to endothelial cells [49]. Furthermore, Nef protein mediates down regulation of ATP binding 
cassette transporter 1 (ABCA1) which ultimately reduces cholesterol removal from macrophages [64,101]. 
 
A – Development of atherosclerosis in HIV-infected individuals and its related thrombotic complications[16]. 
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Fig. (4). Atherosclerosis pathogenesis in HIV-infected patients and its thrombotic complications. 
The figure illustrates the atherosclerotic process in HIV-infected patients and its associated thrombotic complications (A), detailing the proposed 
mechanisms by which the interplay between the virus virion and activated immune cells lead to the development of atherosclerosis in the context of 
infection (B). The virus Gp120, Tat and Nef proteins (1) reduce the secretion of nitric oxide with reduced vasodilation, induce endothelial cells apoptosis 
and promote expression of adhesion molecules for leukocytes. Thus, the human immunodeficiency virus leads to a state of low-grade chronic 
inflammation that increases the risk of atherosclerosis through the activation of macrophages (2), monocytes (3) and lymphocytes (4). The dysfunctional 
endothelium favors the penetration of plasma lipids (LDL) into the subendothelial space where they undergo oxidation (oxLDL). As HIV proteins, lipid 
accumulation itself triggers the exposure of inflammatory and adhesive proteins (i.e., selectins, VCAM, ICAM) that promote the recruitment of 
monocytes into the intima where they transform into macrophages and foam cells by engulfing the accumulated lipids. Given the toxicity of oxidized 
lipids, lipid-rich macrophages undergo apoptotic death, releasing their cytosolic content and generating the necrotic lipid core typical of advanced 
atherosclerotic lesions. The release of factors such as MMPs and TF facilitates plaque rupture leading to thrombus formation.  
EC: Endothelial cells; eNOS: Endothelial nitric oxide synthase; HIV: Human immunodeficiency virus; HLA: Human leukocyte antigen; ICAM: 
Intercellular adhesion molecule; MCP-1: Monocyte chemoattractant protein-1; MMPs: Matrix metalloproteinases; Nef : Negative regulatory factor; 
NO: Nitric oxide; PGI2: Prostacyclin; Tat: Trans-activator of transcription; TF: Tissue factor; SMC: Vascular smooth muscle cells; VCAM: Vascular 
cell adhesion molecule. 
Adapted from Giannarelli et al. (2011)[16] and Shabaz et al. (2015)[39].    
Fig. (4). Contd 
B – Mechanisms involved in the pathogenesis of atherosclerosis in HIV infection[39]. 
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3.4 Coronary heart disease and acute coronary syndrome 
As successful HAART decreased severe immunosuppression-related complications, HIV-IP are currently facing new 
challenges such as CHD [14,15,90]. Although there are some discordant data regarding this matter, current evidence 
suggests that ACS is more frequent in HIV-infected individuals when comparing to the uninfected counterparts [22] and 
it is the main clinical presentation of CHD in the setting of infection [14,70]. In a prospective study of more than 27,000 
HIV-IP from the Veterans Aging Cohort Study (VACS) Virtual Cohort, acute myocardial infarction (AMI) risk among 
HIV-positive veterans with no major CVD risk factors was 2-fold greater than among those who were HIV-negative with 
the same no major CVD risk factor profile [37].   
In HIV-infected individuals, the first manifestation of ACS tends to occur at a younger age [24,33,41] (around 50 years 
old) in current smoking men previously exposed to PIs or NRTIs [41,45]. In a meta-analyses conducted by D’Ascenzo et 
al. [8], the most common ACS presentation at admission was ST-segment elevation myocardial infarction (STEMI), with 
a prevalence of 57.19% (95% CI 47.64–66.75), which is in accordance with the results presented by Boccara et al. [45] 
and Lang et al. [14]. Other less common forms of ACS in the HIV-infected population are unstable angina and non-ST-
segment elevation MI [22], with a global prevalence of 46.08% (95% CI 38.13–54.02) among HIV-IP admitted with a 
clinical presentation of ACS [8]. The increased risk of CAD in the HIV-infected population [10,25,42] is intimately 
related to the progression of the premature atherogenic process in the intima of arterial coronary vessels [46,66]. When 
atherosclerotic plaques become unstable and rupture, partial or total thrombotic occlusion is elicited [19,99] and acute 
ischemic events might occur [6]. 
Furthermore, the immunologic state and viremia appear to be related to ACS in the setting of HIV infection. D’Ascenzo 
et al. [92] found a significant association between a CD4+ cell count less than 200 cells/mm3 and the risk of AMI. Lang 
et al. [54] corroborate these findings reporting that low CD4+ T-cell nadir and HIV-RNA levels >50 copies/mL increase 
the risk of MI [odds ratio (OR) 1.51; 95% CI 1.09–2.10] in HIV-infected individuals. 
Taken together, HIV and ART, by eliciting lipid abnormalities, insulin resistance and lipodystrophy [33,70] may 
contribute to the development of CAD [3]. A large observational study from the Data Collection on Adverse Events of 
Anti-HIV Drugs (DAD) study group demonstrated that prolonged exposure to combined ART increases the incidence of 
MI, showing a RR of MI per year of PIs exposure of 1.16 (95% CI 1.10–1.23) [102]. 
 
3.4.1 Managing acute coronary syndrome in HIV-IP 
The management of ACS in HIV-infected individuals presents no difference when compared to the approach conducted 
in the general population (Table 10). Nevertheless, antithrombotic medications must be prescribed with caution, since 
HIV-IP often present coagulation disorders and thrombocytopenia, thus increasing the risk of severe bleeding events. 
Another concern regarding the use of anti-ischemic medications are the pharmacological interactions with other drugs, 
namely the ones included in HAART regimens, due to the existence of common pathways of metabolism [87].  
Regarding percutaneous coronary intervention (PCI) and coronary artery bypass graft surgery in the set of HIV infection, 
Pham & Torres [10] report no difference in the short-term or long-term mortality, when comparing to HIV-uninfected 
individuals. Boccara et al. [45] further state that PCI can be safely performed during the acute phase of ACS in HIV-
infected patients, with no difference in the rate of clinical restenosis or stent thrombosis after 12 months of a first episode 
of ACS, comparing to a age and sex-matched uninfected group. However, in the prospective multicentre study conducted 
by the authors, HIV-IP were more likely to present recurrent ACS (HR 6.5; 95% CI 1.7–23.9) and to undergo urgent PCI 
at 1-year follow-up (OR 3.29; 95% CI 0.94–11.53) than HIV-uninfected patients. 
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Table 10.  Antithrombotic drugs commonly used in HIV-IP with ACS presentation. 
 
 
ACS: Acute coronary syndrome; AT3: Antithrombin 3; COX: Cyclooxygenase; CYP: Cytochrome P450; HIV-IP: Human immunodeficiency-infected 
patients; PAR-1: Protease-activated receptor 1; RES: Reticuloendothelial system. 
Adapted from Seecheran et al. (2017)[87]. 
 
3.5 HIV infection and cardiovascular risk assessment 
As HIV-infected population ages and rates of CVD-related events increase [103], appropriate cardiovascular assessment 
in this patients is needed to guide risk factor management and ART regimen choice, particularly in individuals at higher 
risk [104]. 
The currently available cardiovascular risk scores include Framingham risk score (FRS), Systematic Coronary Risk 
Evaluation (SCORE), DAD risk equation, Prospective Cardiovascular Münster Study (PROCAM) score, Reynolds, 
VACS and Pooled cohort equations [105] (Table 11). 
FRS, which was developed in the general population, is based on age, gender, systolic blood pressure, total and HDL 
cholesterol levels and smoking status. DAD risk equation, that was specifically developed to estimate cardiovascular risk 
in HIV-IP [88], adds to the FRS variables like family history of CVD, as well as duration and current use of antiretroviral 
drugs namely indinavir, lopinavir and abacavir [103,106]. On the other hand, PROCAM, that differs from FRS by 
including variables such as triglyceride levels and family history of CHD, does not take into account the exposure to ART 
drugs [106].  
Antithrombotic agent Mechanism of action Metabolism Excretion 
Aspirin 
 
Clopidrogel 
Prasugrel 
Ticagrelor 
Cangrelor 
 
Tirofiban 
 
Unfractioned heparin 
Low-molecular-weight heparin 
 
Fondaparinux 
 
Bivalirudin 
 
Rivaroxaban 
 
COX inhibitor 
 
P2Y12 inhibitor  
P2Y12 inhibitor  
P2Y12 inhibitor  
P2Y12 inhibitor  
 
Glycoprotein 2B/3A inhibitor 
 
AT3-dependent inhibitor of factor Xa and thrombin 
AT3-dependent inhibitor of factor Xa and thrombin 
 
AT3-dependent inhibitor of factor Xa 
 
Direct thrombin inhibitor 
 
Direct factor Xa inhibitor 
Hepatic 
 
Hepatic 
Primarily CYP3A4 and CYP2B6 
CYP3A4 
Peripheral circulation 
 
Negligible 
 
Hepatic and RES 
Hepatic and RES 
 
Negligible 
 
Proteolytic cleavage 
 
Both CYP3A4, CYP2J2 and 
CYP-independent mechanisms 
Renal 
 
Renal and fecal 
Renal and fecal 
Hepatic, fecal and renal 
Renal and fecal 
 
Renal and fecal 
 
RES and renal 
RES and renal 
 
Renal 
 
Proteolytic cleavage and renal 
 
Renal and fecal 
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Table 11.  Risk scores and algorithms to assess CVD risk in the general population and among patients with HIV infection. 
 
 
ACC/AHA: American College of Cardiology/American Heart Association; ART: Antiretroviral therapy; ASCVD: Atherosclerotic cardiovascular 
disease; CHD: Coronary heart disease; CVD: Cardiovascular disease; D:A:D: Data Collection on Adverse Events of Anti-HIV Drugs; eGFR: Estimated 
glomerular filtration rate; ESC/EAS: European Society of Cardiology/European Atherosclerosis Society; FIB-4: (years of age x aspartate 
transaminase)/(platelets x alanine transaminase); HDL-C: High-density lipoprotein cholesterol; HIV-1: Human immunodeficiency virus-1; hs-CRP: 
High-sensitivity C-reactive protein; LDL-C: Low-density lipoprotein cholesterol; MI: Myocardial infarction; NCEP ATP III: National Cholesterol 
Education Program Adult Treatment Panel III; NHLBI: National Heart, Lung, and Blood Institute of the National Institutes of Health; PROCAM: 
Prospective Cardiovascular Münster Study; RNA: Ribonucleic acid; SCORE: Systematic Coronary Risk Estimation; Total-C: Total cholesterol; VACS: 
Veterans Aging Cohort Study. 
Adapted from Jacobson et al. (2015)[105]. 
Descriptor Population Age, y Years risk prediction Variables 
 
Guidelines using score 
 
Framingham 
Risk Score 
General 
population from 
Framingham, MA, 
USA 
30-74 10-y risk of CHD 
events; 30-y risk 
of CHD and stroke 
Sex, age, total-C, HDL-C, 
smoking status, systolic blood 
pressure (treated or not 
treated) 
 
NCEP ATP III, Canadian Cardiovascular 
Society, International Atherosclerosis Society, 
National Lipid Association Recommendations 
 
SCORE European 19-80 10-y risk of CVD 
fatality 
Sex, age, total-C or 
total-C/HDL-C, 
systolic blood pressure, 
smoking status 
 
European (ESC/EAS) 
D:A:D D:A:D cohort of 
HIV-1 infected 
men in Europe, 
Argentina, 
Australia and 
USA 
16-85 5-y risk of CVD Number of years on indinavir, 
lopinavir (and/or currently on 
indinavir, lopinavir, abacavir), 
sex, age, current cigarette 
smoker, previous cigarette 
smoker, family 
history of CVD, systolic blood 
pressure, total-C, HDL-C 
 
None 
PROCAM European men 35–65 10-y fatal or nonfatal 
MI or 
sudden cardiac death 
Age, LDL-C, HDL-C, TG, 
smoking status, family 
history of MI, systolic blood 
pressure 
 
None 
REYNOLDS Men and women 
from USA 
Men: 
57-80; 
Women: 
≥45 
10-y risk for CVD Sex, age, smoking status, total-C, 
HDL-C, hs-CRP, parental history 
of MI, glycated hemoglobin 
(if diabetic) 
 
None 
VACS HIV-1 infected 
USA veterans, 
men 
≥18 5-y mortality Age, CD4 count, HIV-1 RNA 
(viral load), hemoglobin, FIB-4, 
eGFR, hepatitis C infection status 
 
None 
Pooled cohort 
equations 
Population-based 
cohort studies 
funded by NHLBI 
Varied 10-y risk of ASCVD Sex, age, race (white or black), 
total-C, HDL-C, systolic blood 
pressure, treatment for high 
blood pressure  
(if systolic >120 mm Hg), 
smoking status 
2013 ACC/AHA Guideline on the Treatment 
of Blood Cholesterol to Reduce 
Atherosclerotic Cardiovascular Risk in 
Adults, National Lipid Association 
Recommendations 
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Risk assessment models developed in the general population, namely FRS, may underestimate the true CVD-related 
events risk in HIV-infected individuals [25,103,107]. Results from previous studies suggest that the DAD equation is the 
most accurate predictor of subclinical atherosclerosis [104,108] and CVD risk in HIV-IP [108]. 
Serrano-Villar et al. [104] found that FRS, SCORE and PROCAM equations underestimate the risk of subclinical 
atherosclerosis and therefore CVD risk in nearly 20% of the cases, proposing that non-invasive tools such as carotid 
ultrasound assessing carotid intima-media thickness (CIMT) might be useful in the recognition of subclinical 
atherosclerosis in HIV-positive patients. Furthermore, the early detection of atherosclerotic plaques in subjects with HIV 
infection and with low measurable CVD risk factors might provide an important insight into the hazard of developing 
end-organ vascular damage [109]. This early detection might also be achieved in asymptomatic HIV-IP with carotid 
vessel wall imaging using cardiovascular magnetic resonance (CMR) [68]. Additionally, coronary computed tomography 
(CT) allows physicians to assess coronary artery calcification (CAC).  
CAC is a marker of atherosclerosis with a high predictive profile for coronary events [16]. Nonetheless, since there is 
evidence of differing plaque morphology in patients with HIV [34,99], some authors suggest that, on the contrary, CAC 
scanning may not adequately assess high-risk patients [50,98]. In this regard, CT angiography scanning is thus presented 
as a valuable research tool to assess non-calcified coronary artery plaque burden and composition [50,110]. Another non-
invasive imaging tool used to evaluate arterial inflammation is 18f-fluorodeoxyglucose positron emission tomography 
(18F-FDG-PET) [2,31,50,100]. 18F-fluorodeoxyglucose is taken up into metabolic pathways, hence allowing imaging of 
metabolically active cells in vulnerable plaque [31] (Fig. 5). 
 
Fig. (5). Representative 18F-FDG-PET (18F-
fluorodeoxyglucose positron emission tomography) 
image from a subject with increased aortic target to 
background ratio (TBR) demonstrated on coronal 
imaging, documenting an active atherosclerotic 
process. 
18F-fluorodeoxyglucose positron emission tomography (18F-
FDG-PET) is a functional imaging technique used to assess 
arterial inflammation, since arterial fluorodeoxyglucose uptake 
provides a measure of macrophage infiltration within 
atheromatous plaques. 
Reproduced from Tawakol et al. (2014)[100], with authors 
permission. 
 
Mooney et al. [67] and Serrano-Villar et al. [104] suggest that standard risk assessment CVD scores like the DAD 
equation might also be further calibrated by incorporating markers of immune status, vascular damage [67,104] and 
inflammation [108]. Supporting this hypothesis, previous findings from Miller et al. [111] show that higher levels of IL-
6 and D-dimer, reflecting an activation of inflammatory [112] and coagulation pathways [22,113,114], are significant 
global predictors of mortality and non-AIDS complications, such as cardiovascular disease, in HIV-IP [HR 1.5; 95% CI 
1.4–1.7 (IL-6) and HR 1.4; 95% CI 1.3–1.6 (D-dimer)] [111]. 
Collectively, the imaging modalities and biomarkers previously presented have elucidated new pathways for investigating 
the pathophysiology of arterial disease and increased CVD risk in patients with HIV infection [50] and thus may improve 
the prediction of CVD endpoints already achieved with established assessment risk scores such as FRS [25]. In this regard, 
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the more recent Reynolds and VACS scores (Table 11), by including HIV-infection related variables such as high-
sensitivity C-reactive protein (hs-CRP) levels and CD4 count, respectively [105], may provide a more accurate evaluation 
of CVD risk in HIV-IP. 
 
3.6 Management of CVD risk factors in HIV infection 
As far as the control of CVD risk in HIV-IP is concerned, guidelines developed for the general population may not reflect 
an optimal disease management [2,51]. Nevertheless, in the absence of specific randomized trials in HIV-infected 
individuals, general strategies to minimize CVD risk in this population include [30] reducing the burden of traditional 
risk factors [21,42] by promoting smoking cessation [2,11,15,24,90], control of blood pressure [30], management of 
insulin resistance and dyslipidemia [2,30,31,85], as well as nutritional counselling [11,15,28] and exercise [11,15,16,30] 
(Fig. 6).  
 
 
 
Fig. (6). Algorithm for cardiovascular disease risk management in HIV-infected patients. 
General strategies to minimize CVD risk in HIV-infected patients include the reduction of traditional risk factors burden by promoting smoking 
cessation, control of blood pressure, management of insulin resistance and dyslipidemia, as well as nutritional counselling and exercise. The intensity 
of efforts to prevent CVD depends on the underlying risk of CVD, which can be estimated: to assess the CVD risk in the following 10 years, the use of 
Framingham equation is recommended. This assessment should be repeated annually in all persons under care, to ensure that the various interventions 
are initiated in a timely way. Regarding ART modification, the advisable options include: (1) replace previous antiretroviral drugs with NNRTI, INSTI 
or another PI/r known to cause less metabolic disturbances, and (2) consider replacing ZDV or ABC with TDF or use an NRTI-sparing regimen. On 
the other hand, and as far as the control of CVD modifiable risk factors is concerned, observational studies suggest that smoking cessation results in 
about 50% less risk of IHD – and this is additive to other interventions. Presented lipid profile target levels are to be used as guidance and are not 
definitive – TC and LDL are expressed as mmol/L with mg/dL in parenthesis –. In case LDL cannot be calculated because of high triglyceride levels, 
the non-HDL-c (TC minus HDL-c) target should be used. Target levels for TG are not listed because an independent contribution from TG to CVD risk 
is uncertain, and hence whether this condition should be treated. As a final note, the management of coagulation disorders in the set of HIV infection 
by prescribing acetylsalicylic acid is controversial. Hence, blood pressure should be reasonably controlled before aspirin use in such a setting. 
ABC: Abacavir; ART: Antiretroviral therapy; CVD: Cardiovascular disease; DBP: Dyastolic blood pressure; DM: Diabetes mellitus; HbA1C: 
Haemoglobin A1C; HDL-c: High-density lipoprotein cholesterol; HIV: Human immunodeficency virus; IHD: Ischaemic heart disease; INSTI: Integrase 
strand transfer inhibitor; LDL: Low-density lipoprotein; NNRTI: Non-nucleoside reverse transcriptase inhibitors; NRTI: Nucleos(t)ide reverse 
transcriptase inhibitors; PI/r: Protease inhibitors pharmacologically boosted with ritonavir; SBP: Systolic blodd pressure; TC: Total cholesterol; TDF: 
Tenofovir disoproxil fumarate; TG: Triglycerides; ZDV: Zidovudine. 
Adapted from Battegay et al. (2016)[69].  
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The contribution of the virus itself for the development of CVD might be reduced by early initiation of ART [2,31,74] in 
primary HIV infection, thus allowing to decrease the long-term cardiovascular system impairment. Regarding the choice 
of the ideal ART regimen for each patient, is not only important to perform a proper initial evaluation of CVD risk, but 
also to preferably chose ART drugs with the least metabolic toxicity profile [31] and to identify the possible drug-drug 
interactions between HAART regimen drugs and other medications used in primary and secondary prevention of CVD 
(Table 9). 
As predicted by Vos et al. [29], the median age of patients receiving ART treatment will be 56.6 years by 2030 and 54% 
of these individuals will be taking at least one more long-term drug aside from ART regimen drugs, namely statins (Table 
12).  
Statin therapy has been proposed when lifestyle modifications and adjustment of ART therapy are not enough [16,90] to 
maintain total cholesterol ≤190mg/dL or LDL-cholesterol ≤115mg/dL [18]. Statins have not only lipid-lowering effects 
but also anti-inflammatory properties, thus contributing to reduce the risk of CVD [2]. However, some statins present 
pharmacological interactions with ART drugs [41]. Simvastatin and lovastatin, which are metabolized by the cytochrome 
P450 CYP3A, are contraindicated to use in co-administration with PIs [35,46], since the latter are potent inhibitors of the 
P450 cytochrome isoenzyme. 
 
Table 12.  Statins: simplified management of dyslipidemia in HIV patients and drug-drug interactions with ART. 
                    Statins 
Pravastatin Fluvastatin Rosuvastatin Atorvastatin Simvastatin Lovastatin 
Dose 20-80 mg qd 20-80 mg qd 5-40 mg qd 10-80 mg qd 10-40 mg qd  
Side effects Gastrointestinal symptoms, headache, insomnia, toxic hepatitis, myalgias/myositis (frequent) and 
rhabdomyolysis (rare) 
Use with PIs Usual dosing 
regimen 
Usual dosing 
regimen 
 
Use lower dose 
and monitor 
 
Use lower 
dose and 
monitor 
Contraindicated Contraindicated 
Use with NNRTIs 
(except delavirdine) 
 
Usual dosing 
regimen 
Usual dosing 
regimen 
Use lower dose 
and monitor 
Use lower 
dose and 
monitor 
Usual dosing 
regimen 
Usual dosing 
regimen 
Observations Not 
metabolized 
by CYP3A4 
and first 
choice 
Metabolized 
by CYP2C9 
and second 
choice 
Contraindicated 
with boosted 
lopinavir and 
atazanavir 
regimens 
 Higher risk of 
rhabdomyolysis 
and myopathy 
with PIs 
Higher risk of 
rhabdomyolysis 
and myopathy 
with PIs 
 
ART: Antiretroviral therapy; CYP: Cytochrome P450; HIV: Human immunodeficency virus; NNRTIs: Non-nucleos(t)ide reverse transcriptase 
inhibitors; PIs: Protease inhibitors; qd: Once a day. 
Adapted from Kellick et al. (2014)[115], Battegay et al. (2016)[69] and Seecheran et al. (2017)[87]. 
 
CONCLUSION 
As up till now, HIV infection will remain a challenging disease in the future [29]. HIV-infected individuals are living 
longer and the risk of non-AIDS morbidity and mortality is raising, thus conditioning an increased need to improve patient 
and health care provider education. In order to detect and properly manage early signs of CVD, routine cardiovascular 
assessment should be performed in these patients, allowing to guide risk factor management and ART regimen choice, 
particularly among individuals at higher risk [104]. Finally, as risk assessment models developed in the general population 
   25 
 
may underestimate the CVD risk in HIV-infected individuals [25,103,107], new imaging available tools such as 18F-FDG-
PET [100] and biomarkers might play an important role on improving the prediction of CVD related-events [25].   
 
LIST OF ABBREVIATIONS 
ABCA1  ATP binding cassette transporter 1 
ACS  Acute coronary syndrome 
AIDS Acquired immunodeficiency syndrome 
AMI  Acute myocardial infarction 
ART  Antiretroviral therapy 
CAC  Coronary artery calcification  
CAD  Coronary artery disease 
CCR5  C-C chemokine receptor 5  
CHD  Coronary heart disease  
CI  Confidence interval 
CIMT  Carotid intima-media thickness  
CMR  Cardiovascular magnetic resonance  
CT  Computed tomography 
CVD  Cardiovascular disease  
DAD  Data Collection on Adverse Events of Anti-HIV Drugs 
ER  Endoplasmic reticulum 
18F-FDG-PET  18F-fluorodeoxyglucose positron emission tomography  
FRS  Framingham risk score  
HAART  Highly active antiretroviral therapy  
HDL  High-density lipoprotein 
HIV  Human immunodeficiency virus  
HIV-IP  Human immunodeficiency virus-infected patients 
HIV-RNA  Human immunodeficiency virus-ribonucleic acid 
HR  Hazard ratio 
hs-CRP  High-sensitivity C-reactive protein 
ICAM-1  Intercellular adhesion molecule-1 
IFN-γ  Interferon-γ 
IL-1  Interleukin-1  
IL-6  Interleukin-6  
IL-8  Interleukin-8 
LDL  Low-density lipoprotein  
MCP-1  Monocyte chemoattractant protein-1  
MI  Myocardial infarction  
Nef  Negative regulatory factor  
NNRTIs  Non-nucleoside reverse transcriptase inhibitors 
NO  Nitric oxide 
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NRTIs  Nucleoside reverse transcriptase inhibitors 
OR  Odds ratio 
PCI  Percutaneous coronary intervention 
PGI2  Prostacyclin 
PIs  Protease inhibitors  
PR  Prevalence ratio 
PROCAM  Prospective Cardiovascular Münster Study 
QTc  Corrected QT 
RR  Relative risk 
SCORE  Systematic Coronary Risk Evaluation  
SMART  Strategies for Management of Antiretroviral Therapy  
STEMI  ST-segment elevation myocardial infarction  
Tat  Trans-activator of transcription 
TNF  Tumor necrosis factor 
TNF-α  Tumor necrosis factor-α 
VACS  Veterans Aging Cohort Study 
VCAM-1  Vascular cell adhesion molecule-1  
vWF  Von Willebrand factor 
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